Australia markets closed

Neuren Pharmaceuticals Limited (NURPF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
13.56+0.88 (+6.91%)
At close: 09:30AM EDT
Full screen
Trade prices are not sourced from all markets
Previous close12.68
Open13.56
Bid0.00 x 0
Ask0.00 x 0
Day's range13.56 - 13.56
52-week range6.17 - 17.20
Volume1,760
Avg. volume162
Market cap1.898B
Beta (5Y monthly)2.01
PE ratio (TTM)16.95
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
All
News
  • PR Newswire

    Neuren Phase 2 trial shows significant improvements in Phelan-McDermid syndrome

    Neuren Pharmaceuticals (ASX: NEU) today announced top-line results from its Phase 2 clinical trial of NNZ-2591 in children with Phelan-McDermid syndrome (PMS). Significant improvement was observed by both clinicians and caregivers from treatment, across multiple efficacy measures. Improvements were consistently seen across many of the core PMS characteristics. PMS has severe quality of life impacts for those living with the syndrome, as well as parents and siblings. There are no approved treatme